Back to Search
Start Over
Establishing a model of seasonal allergic rhinitis and demonstrating dose-response to a topical glucocorticosteroid.
- Source :
-
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology [Ann Allergy Asthma Immunol] 2002 Aug; Vol. 89 (2), pp. 159-65. - Publication Year :
- 2002
-
Abstract
- Background: Symptoms of seasonal allergic rhinitis may vary greatly. Hence, for research purposes, there is a need for disease-like models of allergic rhinitis. In a preliminary study, involving 7 days' challenge with allergen, promising symptom consistency was obtained and dose-response to a glucocorticosteroid could, in part, be demonstrated.<br />Objective: To establish this model of seasonal allergic rhinitis and test the hypothesis that mometasone furoate is more potent than budesonide as an antirhinitis drug.<br />Methods: Thirty-eight patients with seasonal allergic rhinitis received treatment with spray-formulations of placebo, budesonide 64 microg, budesonide 256 microg, and mometasone furoate 200 microg in a double-blind, crossover design. After 3 days' treatment, individualized nasal allergen-challenges were administered daily for 7 days while the treatment continued. Nasal symptoms and peak inspiratory flow (PIF) were recorded.<br />Results: During the last 3 days of allergen challenge without active treatment, consistent around-the-clock symptoms were recorded and recordings during these days were used in the analysis. With few exceptions the active treatments reduced nasal symptoms and improved nasal PIF (P values <0.001 to 0.05). Budesonide caused dose-dependent improvements in evening symptoms, morning nasal PIF, and nasal PIF recorded 10 minutes after allergen-challenge (P values <0.05). Budesonide 256 microg produced greater improvement than mometasone furoate 200 microg for nasal PIF 10 minutes after allergen-challenge (P < 0.05).<br />Conclusion: The present allergen challenge method, producing consistent symptoms and nasal PIF data, emerges as a model of seasonal allergic rhinitis well suited for exploring potency and efficacy of drug intervention. The present data do not support the view that mometasone furoate is a more potent antirhinitis drug than budesonide.
- Subjects :
- Administration, Topical
Adult
Anti-Allergic Agents administration & dosage
Anti-Inflammatory Agents administration & dosage
Budesonide administration & dosage
Cross-Over Studies
Dose-Response Relationship, Drug
Double-Blind Method
Female
Glucocorticoids
Humans
Male
Mometasone Furoate
Nasal Provocation Tests
Pregnadienediols administration & dosage
Rhinitis, Allergic, Seasonal diagnosis
Anti-Allergic Agents therapeutic use
Anti-Inflammatory Agents therapeutic use
Budesonide therapeutic use
Models, Immunological
Pregnadienediols therapeutic use
Rhinitis, Allergic, Seasonal drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1081-1206
- Volume :
- 89
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
- Publication Type :
- Academic Journal
- Accession number :
- 12197572
- Full Text :
- https://doi.org/10.1016/S1081-1206(10)61932-1